231 related articles for article (PubMed ID: 25577040)
1. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
[TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
Mercer SP; Roecker AJ; Garson S; Reiss DR; Meacham Harrell C; Murphy KL; Bruno JG; Bednar RA; Lemaire W; Cui D; Cabalu TD; Tang C; Prueksaritanont T; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2013 Dec; 23(24):6620-4. PubMed ID: 24215892
[TBL] [Abstract][Full Text] [Related]
4. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
5. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.
Kuduk SD; Skudlarek JW; Di Marco CN; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Apr; 24(7):1784-9. PubMed ID: 24630562
[TBL] [Abstract][Full Text] [Related]
7. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
9. Orexin OX
Jacobson LH; Chen S; Mir S; Hoyer D
Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
[TBL] [Abstract][Full Text] [Related]
10. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
11. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.
Boss C; Roch-Brisbare C; Steiner MA; Treiber A; Dietrich H; Jenck F; von Raumer M; Sifferlen T; Brotschi C; Heidmann B; Williams JT; Aissaoui H; Siegrist R; Gatfield J
ChemMedChem; 2014 Nov; 9(11):2486-96. PubMed ID: 25147058
[TBL] [Abstract][Full Text] [Related]
13. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
[TBL] [Abstract][Full Text] [Related]
14. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
16. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
17. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
18. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
[TBL] [Abstract][Full Text] [Related]
19. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.
Gotter AL; Forman MS; Harrell CM; Stevens J; Svetnik V; Yee KL; Li X; Roecker AJ; Fox SV; Tannenbaum PL; Garson SL; Lepeleire ID; Calder N; Rosen L; Struyk A; Coleman PJ; Herring WJ; Renger JJ; Winrow CJ
Sci Rep; 2016 Jun; 6():27147. PubMed ID: 27256922
[TBL] [Abstract][Full Text] [Related]
20. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
